Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces it will release its interim results for the six months ended 30 September 2021 on Thursday 25 November 2021.
Investor presentation
Colin King, CEO, and Chris Lea, CFO, will provide a live presentation relating to the Interim Results via the Investor Meet Company platform on 25 November 2021 at 4:30pm GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet OMEGA DIAGNOSTICS GROUP PLC via:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
Investors who already follow OMEGA DIAGNOSTICS GROUP PLC on the Investor Meet Company platform will automatically be invited.
Contacts:
Omega Diagnostics Group PLC
Colin King, Chief Executive
via Walbrook PR
Chris Lea, Chief Financial Officer
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.
